Who can make this American pharma’s coronavirus drug, licence free?


Gilead Sciences is in talks with chemical and drug makers to produce its experimental drug remdesivir, a potential coronavirus treatment, for Europe, Asia and the developing world, the firm has said. Its patent gives the U.S. company exclusive rights to make the antiviral. But international trade rules allow nations defined by the United Nations as least-developed countries (LDCs) to ignore the patent and make drugs such as remdesivir more affordable in their markets.